{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:10:20Z","timestamp":1789013420316,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.euo.2024.09.015","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T07:32:07Z","timestamp":1729063927000},"page":"417-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prostate-specific Membrane Antigen Positron Emission Tomography Before Reaching the Phoenix Criteria for Biochemical Recurrence of Prostate Cancer After Radiotherapy: Earlier Detection of Recurrences"],"prefix":"10.1016","volume":"8","author":[{"given":"Evelien J.E.","family":"van Altena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard H.E.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke L.","family":"Korbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remco J.J.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wietske I.","family":"Luining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakko A.","family":"Nieuwenhuijzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie L.","family":"van der Pas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem R.N.","family":"van der Voort van Zyp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friso M.","family":"van der Zant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurits","family":"Wondergem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.09.015_b0005","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.015_b0010","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2024.09.015_b0015","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.hoc.2013.08.005","article-title":"Management of patients with biochemical recurrence after local therapy for prostate cancer","volume":"27","author":"Paller","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.euo.2024.09.015_b0020","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s00330-009-1647-4","article-title":"Imaging of prostate cancer local recurrences: why and how?","volume":"20","author":"Rouviere","year":"2010","journal-title":"Eur Radiol"},{"key":"10.1016\/j.euo.2024.09.015_b0025","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2021.02.031","article-title":"Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis","volume":"80","author":"Glicksman","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.015_b0030","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.09.015_b0035","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.2147\/OTT.S117176","article-title":"Androgen deprivation therapy as backbone therapy in the management of prostate cancer","volume":"9","author":"Merseburger","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.euo.2024.09.015_b0040","first-page":"144","article-title":"Hormonal treatment and quality of life of prostate cancer patients: new evidence","volume":"70","author":"Tucci","year":"2018","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.euo.2024.09.015_b0045","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.09.015_b0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2024.09.015_b0055","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.015_b0060","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective Comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2024.09.015_b0065","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.euo.2020.01.002","article-title":"Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the Phoenix criteria for biochemical recurrence after curative radiotherapy","volume":"4","author":"Jansen","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.09.015_b0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2022.02.014","article-title":"Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: implications for potential salvage","volume":"169","author":"Maitre","year":"2022","journal-title":"Radiother Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.euo.2024.09.015_b0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/bju.13616","article-title":"The use of 68Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer","volume":"118","author":"Meredith","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.09.015_b0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41391-019-0163-0","article-title":"The use of 68Ga-PET\/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy","volume":"22","author":"Raveenthiran","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2024.09.015_b0085","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.2967\/jnumed.121.262861","article-title":"18F-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after curative-intent radiation therapy: a bicentric retrospective study","volume":"63","author":"Ilhan","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2024.09.015_b0090","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.09.015_b0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diii.2020.05.007","article-title":"Candidates to salvage therapy after external-beam radiotherapy of prostate cancer: predictors of local recurrence volume and metastasis-free survival","volume":"102","author":"Maoui","year":"2021","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.euo.2024.09.015_b0100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13014-021-01776-8","article-title":"Radiotherapy of oligometastatic prostate cancer: a systematic review","volume":"16","author":"Rogowski","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euo.2024.09.015_b0105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.prnil.2023.10.002","article-title":"Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer","volume":"11","author":"Kawai","year":"2023","journal-title":"Prostate Int"},{"key":"10.1016\/j.euo.2024.09.015_b0110","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.09.015_b0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euo.2024.09.015_b0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0962280209105020","article-title":"Pseudo-observations in survival analysis","volume":"19","author":"Andersen","year":"2010","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.euo.2024.09.015_b0125","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.euo.2024.09.015_b0130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/M19-3286","article-title":"Uses and limitations of the restricted mean survival time: illustrative examples from cardiovascular outcomes and mortality trials in type 2 diabetes","volume":"172","author":"Kloecker","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euo.2024.09.015_b0135","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/JU.0000000000003890","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:51:38Z","timestamp":1744869098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124002244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2588931124002244"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.09.015","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate-specific Membrane Antigen Positron Emission Tomography Before Reaching the Phoenix Criteria for Biochemical Recurrence of Prostate Cancer After Radiotherapy: Earlier Detection of Recurrences","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}